Carmichael Hill & Associates’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $233 | Sell |
62
-1
| -2% | -$4 | ﹤0.01% | 647 |
|
|
2024
Q2 | $597 | Hold |
63
| – | – | ﹤0.01% | 642 |
|
|
2024
Q1 | $4.73K | Buy |
63
+24
| +62% | +$1.8K | ﹤0.01% | 549 |
|
|
2023
Q4 | $6.95K | Buy |
39
+31
| +388% | +$5.52K | ﹤0.01% | 518 |
|
|
2023
Q3 | $5.7K | Buy |
8
+3
| +60% | +$2.14K | ﹤0.01% | 523 |
|
|
2023
Q2 | $25.1K | Hold |
5
| – | – | 0.01% | 365 |
|
|
2023
Q1 | $14.5K | Buy |
5
+2
| +67% | +$5.81K | 0.01% | 421 |
|
|
2022
Q4 | $7.47K | Hold |
3
| – | – | ﹤0.01% | 488 |
|
|
2022
Q3 | $11K | Buy |
3
+1
| +50% | +$3.67K | 0.01% | 456 |
|
|
2022
Q2 | $6K | Hold |
2
| – | – | ﹤0.01% | 534 |
|
|
2022
Q1 | $5K | Buy |
2
+1
| +100% | +$2.5K | ﹤0.01% | 578 |
|
|
2021
Q4 | $6K | Hold |
1
| – | – | ﹤0.01% | 572 |
|
|
2021
Q3 | $5K | Buy |
+1
| New | +$5K | ﹤0.01% | 586 |
|